[Diabetic nephropathy].
Haneda
Masakazu
M
Third Department of Medicine, Shiga University of Medical Science.
D000419:Albuminuria; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000652:urine; D001713:Biphenyl Compounds / Q000627:therapeutic use; D002908:Chronic Disease; D003131:Combined Modality Therapy; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000628:therapy; D003928:Diabetic Nephropathies / Q000145:classification / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D018753:Diet, Protein-Restricted; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000077405:Irbesartan; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D064546:Protein Kinase C beta; D012015:Reference Standards; D013777:Tetrazoles / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015415:Biomarkers; D001713:Biphenyl Compounds; D007004:Hypoglycemic Agents; D007527:Isoenzymes; D013777:Tetrazoles; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D000077405:Irbesartan